Odyssey Health, Inc.
Odyssey Health, Inc. is a Nevada-based medical product development company focused on acquiring, licensing, and advancing healthcare technologies through its operating subsidiaries. Its reported pipeline includes the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device, with development and commercialization intended to occur through third-party partners and distributors.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaHeart monitoring and screening technology under development for medical use.
Choking rescue device designed for emergency response and airway obstruction use.
Potential license fees, royalties, and distribution agreements for approved products.
Acquisition of medical products, assets, and intellectual property for development.
Asiakkaat
Odyssey Health’s end customers are expected to be healthcare providers, distributors, and commercial partners that market approved medical devices. The company’s products are aimed at clinical and emergency-use settings, while its monetization model also depends on licensing partners and distributors that can commercialize the technologies. Because the products are still in development, customer demand is tied to regulatory clearance and partner adoption rather than direct sales today.
Hospitals, clinics, and care settings that would buy or use approved monitoring and rescue devices.
Third-party distributors that sell the company’s products and provide market access.
Commercial partners that pay upfront fees and royalties to market or sublicense products.
Users and institutions that need choking rescue tools for rapid response situations.
Strategia
The company’s strategy is to acquire or develop medical technologies, secure regulatory clearance, and then commercialize them through distributors or licensing partners. It also seeks to expand the addressable market by pursuing additional uses for CardioMap and by building an intellectual-property portfolio that can support future product lines and royalty streams.
Commercial sales depend on FDA or other regulatory approval.
Third-party channels are intended to accelerate market entry and revenue generation.
Additional uses can increase the commercial value of the core technology base.
Maantiede
Odyssey Health is headquartered in Las Vegas, Nevada, and is organized as a U.S. public company with subsidiaries in the United States and Australia. The business is intended to commercialize products in the United States and internationally through licensing and distribution agreements, so future revenue exposure is expected to depend on regulatory approvals and partner networks across multiple markets.
Riskit
Odyssey Health faces the typical risks of an early-stage medical device developer, including regulatory approval risk, clinical and product-development uncertainty, and dependence on third-party commercialization partners. Because it currently has no marketed products, execution risk is concentrated in funding, intellectual property protection, and the ability to build a viable distribution network after approval.
- Regulatory approval riskVaikutus: KriittinenTodennäköisyys: Korkea
Product candidates cannot be sold commercially until cleared or approved by regulators.
Kohdistuu: CardioMap and Save-A-Life
- Funding and going-concern riskVaikutus: KorkeaTodennäköisyys: Korkea
Development-stage operations require external capital before product revenue exists.
Kohdistuu: Corporate liquidity and development spending
- Distribution network riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company expects third parties to market and sell products, which may not materialize or perform well.
Kohdistuu: U.S. and international channel partners
- Intellectual property riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The business depends on patents, trademarks, and proprietary technology to protect value.
Kohdistuu: Medical device technologies and acquired IP
Kirjanpito
Harkinnanvaraiset erätThe company’s ability to continue depends on financing and future commercialization.
Vaikutus: Affects investor assessment of solvency and capital needs
Equity awards can be a meaningful non-cash expense in a development-stage company.
Vaikutus: Affects operating loss and dilution analysis
Borrowings and related interest costs influence reported losses and liquidity.
Vaikutus: Affects net loss and cash flow interpretation
Acquired technologies and IP may need fair value and impairment review.
Vaikutus: Could materially affect balance sheet and earnings
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Adagio Medical Holdings, Inc.
ADGM · Surgical & Medical Instruments & Apparatus
Odyssey Marine Exploration, Inc
OMEX · Water Transportation
Odyssey Marine Exploration is a U.S.-based marine minerals and ocean exploration company focused on identifying, evaluating, and advancing subsea mineral resources.
Cardio Diagnostics Holdings, Inc.
CDIOW · In Vitro & In Vivo Diagnostic Substances
Edgewise Therapeutics, Inc.
EWTX · Pharmaceutical Preparations
HeartBeam, Inc.
BEAT · Surgical & Medical Instruments & Apparatus
Corvex, Inc.
MOVE · Services-Computer Processing & Data Preparation
Päivitetty: 24.9.2026